A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS).

Authors :: Gargiulo L
Ibba L
Malagoli P
Amoruso F
Argenziano G
Balato A
Bardazzi F
Burlando M
Carrera CG
Damiani G
Dapavo P
Dini V
Fabbrocini G
Franchi C
Gaiani FM
Girolomoni G
Guarneri C
Lasagni C
Loconsole F
Marzano AV
Maurelli M
Megna M
Orsini D
Sampogna F
Travaglini M
Valenti M
Costanzo A
Narcisi A
Source :: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2024 Jan; Vol. 38 (1), pp. e113-e116. Date of Electronic Publication: 2023 Aug 29.
Publication Year :: 2024

Subjects :: Humans
Italy
Treatment Outcome
Severity of Illness Index
Antibodies, Monoclonal
Psoriasis drug therapy

Language :: English
ISSN :: 1468-3083
Volume :: 38
Issue :: 1
Database :: MEDLINE
Journal :: Journal of the European Academy of Dermatology and Venereology : JEADV
Publication Type :: Editorial & Opinion
Accession number :: 37611277
Full Text :: https://doi.org/10.1111/jdv.19464

Full Text Access

Tools